Turning Back the Clock: Drug Approvals Hit 25 Year Low
This article was originally published in RPM Report
Executive Summary
You have to go back to 1983 to find a year as bad as 2007 for R&D output. It was a terrible year by any measure. The key question for industry: does it need to learn to subsist on a trickle of new drugs coming to market each year, or is the current drought in fact a sign of a transition to a new, more innovative R&D model? The sparse class of 2007 does offer some glimmers of hope.
You may also be interested in...
What's "New" at FDA?
Amarin, biosimilars and why FDA’s low point was even lower than you thought.
Another Disappointing Year for Drug Approvals
New molecular entity approvals dipped in 2010 and Innovative Commercial Therapies dropped even more sharply. Add to that a significant drop in filings in 2010 and it is hard to be optimistic about a turnaround in approval numbers any time soon.
Another Disappointing Year for Drug Approvals
New molecular entity approvals dipped in 2010 and Innovative Commercial Therapies dropped even more sharply. Add to that a significant drop in filings in 2010 and it is hard to be optimistic about a turnaround in approval numbers any time soon.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: